
Structure-activity relationships of rationally designed AMACR 1A inhibitors
Keywords: α-Methylacyl-CoA racemase (AMACR, P504S); Drug lipophilicity; Enzyme inhibitors; Rational drug design; Structure-activity relationships; AMACR; α-methylacyl-CoA racemase; CDI; carbonyldiimidazole; DAST; (Diethylamino)sulfur trifluoride; DCC; Dicyclohexy